Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 168.80M | 759.90M | -675.90M | 319.20M | -2.16B |
| Total Depreciation and Amortization | 168.20M | 165.40M | 162.10M | 156.80M | 152.60M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 113.10M | -665.50M | 1.20B | -67.20M | 3.16B |
| Change in Net Operating Assets | 60.30M | 272.40M | -197.70M | 125.40M | -631.20M |
| Cash from Operations | 510.40M | 532.20M | 491.50M | 534.20M | 515.30M |
| Capital Expenditure | -153.20M | -157.60M | -154.70M | -163.20M | -159.80M |
| Sale of Property, Plant, and Equipment | 200.00K | 100.00K | 100.00K | 100.00K | 100.00K |
| Cash Acquisitions | -218.50M | -218.50M | -218.50M | -216.70M | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.70M | 186.30M | 187.10M | 181.10M | 45.50M |
| Cash from Investing | -285.80M | -189.70M | -186.00M | -198.70M | -114.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -500.00K | -500.00K | -300.00K | -400.00K | -300.00K |
| Issuance of Common Stock | 14.90M | 15.80M | 15.80M | 17.50M | 18.00M |
| Repurchase of Common Stock | -244.40M | -298.50M | -298.20M | -343.30M | -304.20M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 500.00K | -- | -30.00M | -30.00M | -30.00M |
| Cash from Financing | -229.50M | -283.20M | -312.70M | -356.20M | -316.50M |
| Foreign Exchange rate Adjustments | -9.20M | -16.90M | -6.80M | -15.30M | 4.70M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -14.10M | 42.40M | -14.00M | -36.00M | 89.30M |